RxDoctor Payments Data

Yi Zheng, NP

Family · Bellevue, WANPI 1649713207

Payments from drug & device makers

$607in general payments, 2019–2025

Across 20 payments — averaging $30.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$134
  • Bridgebio Pharma, Inc.$92
  • AstraZeneca$76
  • Pfizer$55
  • Boston Scientific$41
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36
  • plus $173 from 7 others

What the payments were for

  • Food & beverage$607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$607 in reported general payments places this provider in the 70th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$55,445
Medicare patients
282
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban360$505,129
XareltoRivaroxaban52$71,812
EntrestoSacubitril/Valsartan30$45,788
JardianceEmpagliflozin18$28,831
FarxigaDapagliflozin Propanediol21$23,611
MultaqDronedarone Hcl21$17,538
Repatha SureclickEvolocumab14$14,573
Flecainide Acetate170$6,788
Metoprolol Succinate269$5,137
Dofetilide22$4,454
Diltiazem 12hr ErDiltiazem Hcl13$2,576
Losartan Potassium178$2,130
Atorvastatin Calcium205$2,050
Carvedilol106$1,293
Amlodipine Besylate152$1,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$505,129360 claims
NovartisEntresto$35$45,78830 claims
AstraZenecaFarxiga$76$23,61121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,706 family providers in Washington.

Other family in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →